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Objective: To identify neuropsychological predictors of treatment response to cognitive–behavioral therapy
(CBT) and ﬂuoxetine in treatment-naïve adults with obsessive–compulsive disorder (OCD).
Method: Thirty-eight adult outpatients with OCD underwent neuropsychological assessment, including tasks
of intellectual function, executive functioning and visual and verbal memory, before randomization to a
12-week clinical trial of either CBT or ﬂuoxetine. Neuropsychological measures were used to identify predic-
tors of treatment response in OCD.
Results: Neuropsychological measures that predicted a better treatment response to either CBT or ﬂuoxetine
were higher verbal IQ (Wechsler Abbreviated Scale of Intelligence) (p=0.008); higher verbal memory on the
California Verbal Learning Test (p=0.710); shorter time to complete part D (Dots) (pb0.001), longer time to
complete part W (Words) (p=0.025) and less errors on part C (Colors) (pb0.001) in the Victoria Stroop Test
(VST). Fewer perseverations on the California Verbal Learning Test, a measure of mental ﬂexibility, predicted
better response to CBT, but worse response to ﬂuoxetine (p=0.002).
Conclusion: In general, OCD patients with better cognitive and executive abilities at baseline were more prone
to respond to either CBT or ﬂuoxetine. Our ﬁnding that neuropsychological measures of mental ﬂexibility
predicted response to treatment in opposite directions for CBT and ﬂuoxetine suggests that OCD patients
with different neuropsychological proﬁles may respond preferentially to one type of treatment versus the
other. Further studies with larger samples of OCD patients are necessary to investigate the heuristic value
of such ﬁndings in a clinical context.© 2012 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
Obsessive–compulsive disorder (OCD) is a chronicmental illness as-
sociated with signiﬁcant distress and impaired functioning (Koran,
2000; Leon et al., 1995). Its lifetime prevalence is estimated to be 2–
3% (Ruscio et al., 2010a, 2010b; Weissman et al., 1994) and accumulat-
ing evidence supports the efﬁcacy of two treatment interventions:
cognitive–behavioral therapy (CBT), which includes exposure and re-
sponse prevention (Foa et al., 2005) and pharmacotherapy, primarily
serotonin reuptake inhibitors (Fineberg and Gale, 2005). Overall, up to
60% of patients receiving one of these treatments or a combination of
the two will exhibit a clinically signiﬁcant reduction in obsessive–edical School at São Paulo, Rua
SP, Brazil.
nte).
vier OA license. compulsive symptoms (OCS), although residual symptoms are often
the rule rather than the exception (Pallanti et al., 2002).
Neuropsychological approaches have proven to be important tools
in the investigation of cognitive functioning in OCD (Kuelz et al.,
2004; Olley et al., 2007). In previous studies, certain neuropsycholog-
ical domains, specially related to executive functioning, such as plan-
ning, cognitive ﬂexibility, response inhibition, decision making and
attentional bias/vigilance, were found to be impaired in OCD patients
(Bérdard et al., 2009; Bespalov et al., 2010; Bolton et al., 2000;
Cavedini et al., 2002; Chamberlain et al., 2005; Menzies et al., 2008;
Olley et al., 2007; Shin et al., 2010) although inconsistent results
have been reported (Kuelz et al., 2004). Possible reasons for dispar-
ities in some neuropsychological ﬁndings in OCD might be explained
by methodological issues such as small and heterogeneous samples of
OCD participants, matching criteria and comorbidities, and particular-
ly previous exposure to medications (Kuelz et al., 2004; Simpson et
al., 2006).
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such as those in nonverbal memory, set shifting, planning, organizational
skills and problem-solving may improve with CBT and pharmacological
treatments (Kuelz et al., 2006; Park et al., 2002). There are also otherﬁnd-
ings showing that some neuropsychological impairments, such as inhibi-
tory control and verbal ﬂuency, remain present even after successful
treatment (Kim et al., 2002; Thienemann and Koran, 1995). Furthermore,
impairments in executive function domains have been shown to be asso-
ciatedwith treatment response to speciﬁc treatmentmodalities (Cavedini
et al., 2002; Flessner et al., 2010; Fontenelle et al., 2001). For example,
poorer response to CBT has been associated to lower scores in tests of se-
mantic verbal ﬂuency and learning of visual association pairs (Cavedini et
al., 2002), whereas impaired set-shifting ability, measured by the
Wisconsin Card Sorting Test (WCST), has been associated with better
therapeutic response to ﬂuoxetine (Fontenelle et al., 2001). Moreover,
poorer decision-making performance predicted poorer outcome to phar-
macological treatment (Cavedini et al., 2002). In youthswith OCD, poorer
performance on theRey–Osterrieth Complex Figure Test predicted poorer
response to treatment, particularly among those receiving CBT alone
(Flessner et al., 2010). On the other hand, some trials have found no asso-
ciation between pretreatment neuropsychological performance (visuo-
spatial construction, visual memory, and set-shifting) and response to
CBT (Bolton et al., 2000; Moritz et al., 2005).
Notwithstanding the studies described above, neuropsychological
investigations designed to examine predictors of treatment response
in clinical trials comparing simultaneously the twomain modalities of
intervention are lacking in OCD. This is unfortunate, given evidence in
literature suggesting distinct neurobiological mechanisms of action of
CBT and pharmacotherapy in OCD (Hoexter et al., 2012).
Therefore, to address these limitations, this study aimed to evalu-
ate neuropsychological predictors of treatment response using a
broad neuropsychological battery, focusing mainly on executive func-
tions. The sample consisted of treatment-naïve adult OCD patients
submitted to a 12-week randomized clinical trial of CBT and ﬂuoxe-
tine. The selection of a treatment-naïve population aims to exclude
the potential confounding bias of previous treatments on neuropsy-
chological domains (Bolton et al., 2000; Kang et al., 2003; Kim et al.,
2002; Krishna et al., 2011). We hypothesized that better neuropsy-
chological performance in respect to executive function, i.e., inhibito-
ry control; cognitive ﬂexibility and planning would predict greater
response to both treatment modalities (CBT or ﬂuoxetine). However,
given that CBT is assumed to rely on executive functions, speciﬁcally
cognitive ﬂexibility (Beck, 1995), patients with better performance
on mental ﬂexibility and learning would be more likely to improve
after CBT if compared to ﬂuoxetine. Additionally, we explored wheth-
er sociodemographic and clinical variables could inﬂuence treatment
response.2. Methods
The present study is a part of a research protocol evaluating multiple
neurobiological measures in treatment-naïve OCD patients (Hoexter et
al., 2009). Study subjects participated in a larger clinical trial designed to
compare the effectiveness of group CBT versus ﬂuoxetine (Belotto-Silva
et al., 2012) (registration at http://clinicaltrials.gov — NCT00680602). A
detailed description of the assessment instruments (training, and reliabil-
ity) can be found in the literature (Miguel et al., 2008). From 2006 to
2008, 369 subjects underwent clinical and psychiatric medical assess-
ment in the OCDoutpatient clinic at the Institute &Department of Psychi-
atry, University of São PauloMedical School, São Paulo, Brazil. From these,
50 treatment-naïve OCD patients fulﬁlling inclusion criteria accepted
participation in this study.
The required written informed consent was approved by the Re-
search Ethics Committee of the University of Sao Paulo and signed
by all participants.2.1. Inclusion and exclusion criteria
Inclusion criteria were: age between 18 and 65 years; DSM-IV
diagnosis for OCD; score≥16 on Y-BOCS; and, in the presence of
other comorbid Axis I diagnoses, OCD as the primary and most severe
diagnosis in terms of impairment. Patients were excluded if: they had
prior exposure to any psychotropic medication or cognitive behavior
therapy (at least 12 sessions); had a general medical condition (such
as history of head injury with post-traumatic amnesia); or had severe
mental illness other than OCD (i.e., psychotic disorder, active phase
bipolar disorder, major depression with signiﬁcant risk of suicide).
2.2. Clinical assessment
A broad range of clinical instruments was used, including the Struc-
tured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (First et al.,
1995), the Y-BOCS, the Dimensional Y-BOCS (DY-BOCS) (Rosário-
Campos et al., 2006), the Beck Depression Inventory (BDI) (Beck et al.,
1961) and the Beck Anxiety Inventory (BAI) (Beck et al., 1988) (see
Hoexter et al., 2009; Belotto-Silva et al., 2012 for more details).
2.3. Neuropsychological assessment
Prior to treatment initiation, patients underwent a neuropsycho-
logical evaluation. Testing averaged approximately three hours. The
application of neuropsychological tests followed a set presentation
order. Instruments that required attention and memory were admin-
istered early in the session when subjects were less susceptible to
fatigue. The application of tests and scoring were performed by a
trained neuropsychologist who was blinded to group assignment.
Given that previous studies performed in OCD patients have empha-
sized impairments in speciﬁc neuropsychological domains involving
executive functions (planning, cognitive ﬂexibility, response inhibi-
tion, decision making and attentional bias/vigilance) (Cavedini et al.,
2002; Kuelz et al., 2004; Menzies et al., 2008; Shin et al., 2010), we se-
lected the following tests:
2.3.1. Intellectual function
The Wechsler Abbreviated Scale of Intelligence (WASI) was used to
estimate full IQ (Wechsler, 1999).
2.3.2. Attention
Digit Span (Forward and Backward) was used to assess auditory
attention and short-term retention capacity (Wechsler, 1981).
Trail Making Test (TMT) was used to assess complex visual scan-
ning, visual search speed, visual attention, mental ﬂexibility (Part
B), and inhibitory control (Wechsler, 1997a, 1997b).
2.3.3. Executive function
Object Alternation Task (OAT) (Freedman, 1990) was used as a
measure of cognitive ﬂexibility.
Hayling and Brixton Test (Burgess and Shallice, 1997) evaluated
initiation speed as well as response suppression, while the Brixton
Spatial Anticipation (Burgess and Shallice, 1997) test was used as a
rule attainment task.
TheWisconsin Card Sorting Test (WCST) (Heaton, 1981) assessed ab-
stract behavior, set shifting, response inhibition and mental ﬂexibility.
Victoria Stroop Test (VST) (Regard, 1981) was used to determine
selective attention, mental ﬂexibility and inhibitory control.
The Iowa Gambling Task (IGT) (Bechara et al., 1994) evaluated
decision making.
2.3.4. Memory and learning
Logical Memory (Wechsler, 1997a, 1997b) assessed contextualized
short- and long-term memory.
Table 1
Demographic characteristics of obsessive–compulsive disorder (OCD) patients divided
for groups of treatment.
Variable CBT
(n=18)
Fluoxetine
(n=20)
p-value
Mean SE Mean SE
Age 32.7 9.7 31.1 10.8 0.65
freq % freq % p-value
Gender
Female 13 72.2 10 50.0 0.16
Socioeconomic status
Classes a/b (higher) 12 66.7 10 50.0 0.29
Classes c/d/e (lower) 6 33.3 10 50.0
Level of educationa
Higher 5 27.8 8 40.0 0.73
Middle 12 66.7 11 55.0
Lower 1 5.6 1 5.0
Right-handed 17 94.4 19 95.0 0.94
Abbreviations: CBT: cognitive behavior therapy.
a Higher: complete tertiary education; middle: incomplete tertiary and complete
secondary education; lower: incomplete secondary education.
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measured verbal memory and learning.
The Brief Visual Motor Test — Revised (BVMT-R) (Benedict, 1997)
was used to measure visual memory and learning.
The Rey–Osterrieth Complex Figure (ROCF) (Osterrieth, 1944)
assessed visual–spatial constructional ability and visual memory.
2.3.5. Language
The COWA (Spreen and Strauss, 1998) assessed verbal ﬂuency
under deﬁned conditions.
2.4. Treatment allocation
After accepting to participate, patients were sequentially allocated
to receive treatment between group CBT or ﬂuoxetine. This procedure
aimed to minimize possible differences between groups before treat-
ment by adjusting for prognostic factors, such as initial Y-BOCS score,
gender, and age (Fossaluza et al., 2009).
2.5. Treatment protocols
Patients allocated to CBT were divided into subgroups of 6–8
patients and attended weekly 2-hour therapy sessions for 12 weeks,
with three additional follow-up sessions. The protocol emphasized
exposure and response prevention exercises as well as cognitive tech-
niques, such as correction of thoughts/beliefs and relapse prevention
strategies. Patients allocated to pharmacological treatment received
ﬂuoxetine (up to 80 mg/day or maximum tolerated dosage) for
12 weeks, starting at 20 mg/day in the ﬁrst week, with 20 mg weekly
increases (Belotto-Silva et al., 2012).
2.6. Criteria for treatment response
The primary outcome measure for treatment response in this study
was percent reduction in baseline Y-BOCS scores.
Treatment response was analyzed as a continuous variable, in
terms of degrees of response, calculated as follows:
Y BOCSinitial−Y BOCSfinalð Þ
Y BOCSinitial
 100:
2.7. Statistical analyses
Statistical analysis was performed using the computer program R,
version 2.9.0 and the Statistical Package for Social Sciences (SPSS) for
Windows, version 14.0.P. Statistic indicators inferior to 0.05 were
considered statistically signiﬁcant.
The Mann–Whitney or the chi-square tests were used to evaluate
demographic and clinical variables. Correlation between neuropsycho-
logical testing results and treatment response (deﬁned as the reduction
of initial Y-BOCS scores) was tested using Pearson's correlation
coefﬁcient.
Generalized linear models (Mccullagh and Nelder, 1989) were
employed to determine the combined inﬂuence of neuropsychological
parameters on treatment response. Only data from patients who com-
pleted the 12-week protocol was used. The following variables were
included: treatment type (i.e., CBT or ﬂuoxetine), sociodemographic
variables (i.e., gender, age and years of formal education), clinical vari-
ables (i.e., Y-BOCS, Beck-A and Beck-D scores) and those neuropsycholog-
ical variables which presented minimal correlation (p-valueb0.15) with
treatment response (i.e., CVLT-II perseverative responses, CVLT-II Total
recall, IGT A+B,WCST learning to learning, Matrix Reasoning and Verbal
IQ on the WASI, VST: part W—word, part C—colors, part C—colors errors,
part D—dots, TMTB time and errors).We includedﬁrst-order interactions
between sociodemographic, clinical and neuropsychological variablesand treatment type. Theﬁnal variable and test protocolmodelwas chosen
based on the AIC (Akaike Information Criterion) and BIC (Bayesian Infor-
mation Criterion).
In order to test the power of our statistical model, we executed a
“power analysis” using the G*Power v. 3.1.3. Including 38 subjects and
10 explanatory variables, we obtained a 0.9999983 “adequateness”
index to validate this model.
3. Results
3.1. Sample
Of the 50 OCD patients initially enrolled in the trial, 12 (24%) dropped
out in a very early stage of the clinical trial (5 participants from the CBT
and 7 from the ﬂuoxetine group). Reasons for abandonment in the CBT
group were fast initial reduction of symptoms (n=2), treatment alloca-
tion dissatisfaction (n=2), and failure to comply with sessions (n=1).
Reasons for abandonment in the ﬂuoxetine group included failure to
comply with consultations (n=4), treatment allocation dissatisfaction
(n=2) and intolerable side effects (n=1). Therefore, only data from
the completers (CBT=18 and ﬂuoxetine=20) was analyzed.
3.2. Demographic and clinical characteristics in treatment groups (CBT
and ﬂuoxetine)
At baseline, patients assigned to the two treatment groups (CBT and
ﬂuoxetine) were similar in terms of demographic (Table 1) and clinical
characteristics (Table 2). As can be observed, there was no statistical
signiﬁcant difference between groups in the major sociodemographic
and clinical variables.
3.3. Treatment outcome
Themean reduction in Y-BOCS score after treatmentwas 36% (36.0%
for the CBT group and 36.1% for theﬂuoxetine group, p=0.8). The effect
size (Cohen's d) between initial and ﬁnal YBOCS for CBT was 1.17, and
for ﬂuoxetine, 1.53, without signiﬁcant statistical difference between
treatments (p=0.08).
3.4. Neuropsychological performance at baseline
Intelligence and neuropsychological measures were similar be-
tween treatment groups, with the exception of similarities (WASI),
CVLT-II measures — total recall, short delay cued recall, long delay
Table 2
Psychopathological features of OCD patients, by treatment group.
Measure Treatment Statistics
CBT
(n=18)
Fluoxetine
(n=20)
Mean SE Mean SE p-value
BDI 17.6 9.5 17.2 7.5 0.88
BAI 16.2 13.1 16.7 10.0 0.89
Age of onset of OCD 14.8 8.7 11.8 7.2 0.22
DY-BOCS I (aggression, violence) 6.9 4.7 11.0 21.3 0.42
DY-BOCS II (sexual, religious) 8.7 22.9 10.8 21.4 0.76
DY-BOCS III (arrangement) 13.1 21.8 9.0 3.0 0.40
DY-BOCS IV (washing) 6.4 5.0 15.8 28.9 0.18
DY-BOCS V (hoarding) 7.9 23.0 8.2 21.6 0.96
DY-BOCS global 21.2 0.8 22.5 1.0 0.32
Y-BOCS obsessions 13.2 2.4 12.1 3.6 0.26
Y-BOCS compulsions 13.0 3.4 13.0 2.5 0.99
Y-BOCS global 26.3 5.5 25.2 5.1 0.51
% Reduction in Y-BOCS global 36.1 6.0 36.0 6.5 0.99
Comorbidity freq % freq % p-value
Major depressive episode 5 27.7% 9 45.0 0.35
Dysthymic disorder 4 22.2% 2 10.0% 0.30
Bipolar disorder 1 5.6% 1 5.0% 0.93
Generalized anxiety disorder 1 5.6% 0 0.0% 0.82
Social phobia 6 33.3% 8 40.0% 0.75
Speciﬁc phobia 4 22.2% 4 20.0% 0.38
Skin picking 2 11.1% 3 15.5% 0.72
Trichotillomania 1 5.6% 2 10.0% 0.61
Body dysmorphic disorder 1 5.6% 1 5.0% 0.56
Pain disorder 1 5.6% 0 0.0% 0.28
Compulsive buying 1 5.6% 2.0 10.0% 0.87
PTSD 0 0.0% 3.0 15.0% 0.18
ADHD 1 5.6 2 10.0 0.74
Panic disorder with agoraphobia 0 0 2 10.0% 0.16
Intermittent explosive disorder 3 16.7% 3 15.0% 0.55
Abbreviations: DY-BOCS = Dimensional Yale–Brown Obsessive–Compulsive Scale.
I — aggression, violence and natural disasters; DY-BOCS, II — sexual and religious; III —
symmetry, ordering, arranging; IV — contamination and cleaning; V — hoarding; PTSD
— post-traumatic stress disorder; ADHD — attention deﬁcit hyperactivity disorder.
Table 3
Pre-treatment neuropsychological test results of 38 OCD patients.
Neuropsychological variables CBT Fluoxetine
Intelligence Mean SE Mean SE p-value
Full IQ 92.00 3.02 91.35 2.58 0.89
Vocabulary 47.33 2.51 47.10 1.93 0.23
Similarities 31.39 1.50 35.10 0.95 0.04
Verbal IQ 86.17 3.39 92.30 2.56 0.15
Block design 41.28 12.23 36.80 14.85 0.31
Matrix 20.83 1.76 22.55 1.56 0.47
Performance IQ 94.0 3.99 92.80 3.33 0.81
Visuospatial memory
ROCF Copy 32.58 0.89 33.02 0.78 0.71
Delayed recall 15.81 1.68 17.37 1.43 0.36
Planning score 3.67 0.41 3.80 0.40 0.81
BVMT Total 24.11 1.80 25.55 1.25 0.51
Learning 5.00 0.46 4.15 0.37 0.16
Delayed recall 10.06 0.61 10.35 0.39 0.69
Percent retained 96.50 3.26 97.00 1.27 0.88
Recognition hits 5.72 0.13 5.80 0.09 0.63
False alarms 0.06 0.56 0.00 0.00 0.33
Discrimination index 5.94 0.22 5.80 0.09 0.55
Response bias 0.39 0.01 0.48 0.02 0.04
Verbal memory
Logical memory (WMS-R) immediate 22.06 1.55 24.05 1.41 0.35
Delayed recall 18.88 1.74 18.80 1.37 0.97
CVLT Total recall 49.83 3.41 59.45 1.79 0.01
Intrusions 1.00 0.16 1.05 0.08 0.92
Perseverationsa 7.67 0.27 6.00 0.23 0.46
Learning 4.94 0.70 5.10 0.50 0.06
Delayed recall 11.06 0.71 12.70 0.59 0.08
Recognition hits 14.67 0.44 15.80 0.11 0.02
Recognition false alarms 0.50 0.20 0.50 0.25 0.02
Attention and inhibitory control
Trail A 36.72 2.25 40.20 3.39 0.40
Errors 0.06 0.56 0.05 0.50 0.00
Trail B 89.66 9.55 95.95 11.22 0.67
Errors 0.11 0.11 0.55 0.26 0.15
Letter number sequence 10.22 0.71 9.58 0.59 0.49
Digit span Total 16.22 1.04 15.10 0.64 0.89
Direct 9.44 0.51 9.25 0.38 0.76
Indirect 6.78 0.72 5.85 0.39 0.25
Stroop
test
1st condition 14.29 1.23 14.10 0.73 0.89
Errors 1st condition 0.00 0.00 0.20 0.11 0.12
2nd condition 15.88 0.90 16.60 0.78 0.40
Errors 2nd condition 0.06 0.05 0.10 0.06 0.65
3rd condition 25.17 1.51 26.60 1.77 0.55
Errors 3rd condition 0.47 0.17 1.00 0.32 0.18
Stroop effect 14.29 1.35 14.10 1.61 0.45
Attention and inhibitory control (continuation)
COWA 36.93 2.66 39.56 3.00 0.35
OAT Hits 33.80 1.67 37.42 0.48 0.28
Errors 5.27 1.43 8.11 3.11 0.45
Go/No Go Omissions 6.25 3.42 9.57 4.43 0.62
Comissions 6.25 2.39 8.14 1.93 0.56
Cognitive ﬂexibility
WCST Completed categories 2.77 0.31 2.85 0.31 0.64
Perseverative responses 5.88 1.96 5.55 1.08 0.91
Perseverative errors 5.16 1.36 4.85 2.04 0.68
Perseverative error
percentage
8.79 2.47 5.91 1.69 0.33
Non‐perseverative errors 14.61 1.57 15.25 1.95 0.80
Loss of set 0.55 0.20 0.35 0.16 0.43
Trails to complete 1st
category
15.33 2.81 12.15 0.48 0.24
Conceptual level responses 58.71 3.99 62.42 3.53 0.48
Learning to learning −4.44 2.61 −5.11 2.01 0.83
(continued on next page)
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patients allocated to ﬂuoxetine showed better performance (Table 3).
3.5. Clinical predictors of treatment response
In our sample, age emerged as a predictor of treatment response to
ﬂuoxetine andhad a small inﬂuence in predicting response toCBT. Elderly
individuals responded better to ﬂuoxetine, whereas, less extensively,
younger individuals responded better to CBT (pb0.001). In terms of the
severity of OCS, higher initial Y-BOCS scores predicted a better response
to both treatments (pb0.001).
3.6. Neuropsychological predictors of treatment response
The neuropsychological domains that were predictive of response
to treatment in this study were as follows (Table 4):
Intelligence: a higher score on the verbal IQ section of theWechsler
Abbreviated Scale of Intelligence was found to be predictive of a
better response to CBT and had a small inﬂuence on response to
ﬂuoxetine (p=0.008).
Verbal memory and learning: better performance on the total recall
portion (Trials 1–5 correct) of the CVLT-II translated to a better re-
sponse to ﬂuoxetine and presents a slight inﬂuence to CBT re-
sponse (p=0.013).
Mental ﬂexibility: fewer perseverations (CVLT-II) predicted a bet-
ter response to CBT (p=0.002) but worse response to ﬂuoxetine
(p=0.003).
Table 3 (continued)
Neuropsychological variables CBT Fluoxetine
Intelligence Mean SE Mean SE p-value
Hayling
test
A 3.21 0.28 3.31 0.28 0.80
B 3.92 0.69 3.75 0.51 0.83
C 5.35 0.65 6.00 0.50 0.43
Total 12.64 1.15 13.06 0.85 0.76
Brixton
test
26.66 2.72 25.75 2.10 0.78
Decision making — IGT
Block 1 −1.62 1.34 −1.20 0.80 0.77
Block 2 −0.75 1.16 −2.10 0.94 0.37
Block 3 1.40 1.34 0.28 1.42 0.50
Block 4 −1.20 1.09 −2.14 1.16 0.79
Block 5 −2.40 2.12 0.57 1.40 0.30
General tendency −3.20 2.99 −2.71 5.03 0.94
Abbreviations: ROCF — the Rey–Osterrieth Complex Figure Test, BVMT — Brief Visual
Memory Test, WMS-R — Wechsler Memory Scale Revised, CVLT — California Verbal
Learning Test, COWA — the Controlled Oral Word Association, OAT — Object Alterna-
tion Test, WCST — Wisconsin Card Sorting Test, and IGT — Iowa Gambling Test.
a No difference is evident here because less perseveration predicted better response
to CBT treatment while more perseveration predicted better response to ﬂuoxetine.
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the Victoria Stroop Test (VST) was predictive of a better response
to both treatments (pb0.001). A longer time to completion of part
W (Words) was predictive of a better response to both treatments
(p=0.025). In part C (Colors), OCD patients who committed few
errors showed a better response to both treatments, a result
much more pronounced for CBT (pb0.001).
3.7. Hypothetical predictive model of treatment response
Considering that our generalized linear model was appropriate
and had good treatment response predictive power, we hypothetical-
ly and illustratively explored the Y-BOCS expected response rate of a
given patient, based on his/her demographic, clinical characteristics
and neuropsychological performance. For instance, as can be seen in
Table 5, an OCD patient with age 39, initial YBOCS 25, and the follow-
ing neuropsychological performance: 50 (raw score) on CVLT total
recall, 114 (raw score) on verbal IQ, 20 s to complete the VST part
D, 30 s to complete the VST part W, and 2 errors on VST part C,Table 4
Neuropsychological and clinical predictors of treatment responsea.
Independent variables Coefﬁcient SE p-value
(Intercept) −214.791 58.821 0.0017
Type of treatment −9.893 64.937 0.8805
Age −0.399 0.395 0.325
Y-BOCS at baseline 3.717 0.614 b0.001
BDI 0.744 0.383 0.066
Verbal IQ (WASI) 2.379 0.809 0.008
CVLT-II total recall 0.216 0.573 0.710
CVLT-II perseverative responses −2.123 0.602 0.002
VST part D (Dots) time −5.037 0.847 b0.001
VST part W (Words) time 2.685 1.104 0.025
VST part C (Colors) errors −39.459 9.087 b0.001
Type of treatment: age 2.655 0.492 b0.001
Type of treatment: verbal IQ (WASI) −2.696 0.920 0.008
Type of treatment: CVLT-II total recall 1.988 0.728 0.013
Type of treatment: CVLT-II perseverative
responses
4.183 1.236 0.003
Type of treatment: VST part C (Colors) errors 30.820 10.366 0.007
Abbreviations: Y-BOCS — Yale Brown Obsessive–Compulsive Scale, BDI — Beck Depres-
sion Inventory, WASI—Wechsler Abbreviated Scale of Intelligence, CVLT-II— California
Verbal Learning Test, and VST — Victoria Stroop Test.
a Linear regression: dependent variable: % of response; independent or predictive variables:
type of treatment (ﬂuoxetine or CBT); age; gender; years of education; age at onset of
OCD; Y-BOCS score; BDI score, BAI score; and all neuropsychological measures.would present a 37% improvement in Y-BOCS scores if submitted to
CBT and 12% if submitted to ﬂuoxetine. On the other hand, another
patient with the same age 39, initial YBOCS 25, and the following
neuropsychological performance: 40 (raw score) on CVLT total recall,
111 (raw score) on verbal IQ, 15 seconds to complete the VST part D,
25 s to complete the VST part W, and 1 error on VST part C, would
present a 18% improvement in Y-BOCS scores if submitted to CBT
and 57% if submitted to ﬂuoxetine.
4. Discussion
To our knowledge, this is the ﬁrst study to investigate neuropsy-
chological predictors of treatment response in a sample of adult
treatment-naïve OCD patients submitted to CBT or ﬂuoxetine in a
randomized design. Both treatments were shown to be effective in
reducing obsessive–compulsive symptoms. The advantage of includ-
ing OCD patients never submitted to treatment is the exclusion of
potentially confounding effects of previous interventions on neuro-
psychological measures.
Congruently with our initial hypothesis, higher baseline neuropsy-
chological performance predicted better treatment response to both
treatments, with the exception of mental ﬂexibility, in which fewer
perseverations predicted better response to CBT, but worse response
to ﬂuoxetine.
4.1. Sociodemographic and clinical predictors of treatment response
In our sample, older patients had a better treatment response toﬂuox-
etine, whereas, less extensively, among those who were submitted to
CBT, younger individuals responded better. In previous studies age has
not been associated with treatment outcome in OCD (Ginsburg et al.,
2008; Maher et al., 2010). On the other hand, some studies have found
that longer periods without being treated were predictive of worse re-
sponse to pharmacological treatments for OCD (Ravizza et al., 1995),
suggesting that longer illness duration (which may be correlated to age)
could be linked to the development of neurobiological abnormalities
that make the disorder more resistant to pharmacological response.
Our ﬁndings, however, go in the opposite direction: older patients
in this treatment naïve sample had a better treatment response to
ﬂuoxetine. We do not have a clear understanding for this discrepancy.
We speculate that other clinical variables associated to treatment
response may have played a role on this regard. Many clinical vari-
ables, beyond age and illness duration, are associated with poor
response to treatment in OCD, such as more severe OCD symptoms,
anxiety and depression (Ferrão et al., 2006; Mataix-Cols et al., 1999),
earlier onset of obsessive–compulsive symptoms (Fontenelle et al.,
2003; Ravizza et al., 1995; Rosário-Campos et al., 2001) and a greater
comorbidity proﬁle (McDougle et al., 1990; Shavitt et al., 2006).
Interestingly, in an exploratory analysis, dividing our patients in the
ﬂuoxetine-group (n=20) according to the median age (30 years), sub-
jects with age≤30 presented signiﬁcantly higher scores on measures of
depression (BDI) (mean±SD: 21.4±5.5), anxiety (BAI) (mean±SD:
21.8±8.1) and had an earlier onset of obsessive–compulsive symptoms
(mean±SD: 8.5±1.7) compared to subjects with age>30 (BDI
mean±SD: 12±6.4; BAI mean±SD 10.3±8.7: and age of onset of OCS
mean±SD: 15.5±9.5) (p≤0.05). These subgroups did not differ in
terms of obsessive–compulsive symptom severity (Y-BOCS scores
mean±SD: 25.7±5.0 for patients with age≤30 and Y-BOCS scores
mean±SD: 24.6±5.5 for patients with age>30). Therefore, in our
study, older patients may have responded better to ﬂuoxetine because
they were less depressed and anxious and had a later onset of OCS, in
spite of longer illness duration.
In addition, our ﬁndings suggested that younger patients submitted
to CBT presented a better treatment response than older patients. Given
that CBT is assumed to rely on cognitive skills known as executive
functions (Beck, 1995), one possible reason for this result may be the
Table 5
Neuropsychological and clinical predictors of treatment response — an example in a clinical practice.
Type of treatment Age YBOCS initial CVLT total recall Verbal IQ VST part D
Time
VST part W
Time
VST part C
Errors
Expected response %
Patient 1 CBT 39 25 50 114 20 30 2 37%
Fluoxetine 39 25 50 114 20 30 2 12%
Patient 2 CBT 39 25 40 111 15 25 1 18%
Fluoxetine 39 25 40 111 15 25 1 57%
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subjects (Gorenstein and Papp, 2007). However, this interpretation
should be taken cautiously. It should be acknowledged that in our statis-
tical model, age exhibited a weak inﬂuence in predicting CBT response
(Table 4). Moreover, our OCD sample comprised patients with a maxi-
mum age of 65, precluding us to compare our ﬁndings to other studies
that found cognitive rigidity in older subjects (Gorenstein and Papp,
2007).
Though the great majority of treatment response studies suggests
that more severe OCD symptoms predict worse response to treatment
(Ferrão et al., 2006; Mataix-Cols et al., 1999), our ﬁndings have
shown that more severe OCS were predictive of better treatment re-
sponse to CBT and ﬂuoxetine. It should be highlighted that previous
treatment response studies included patients with OCD that had al-
ready been treated, whereas in our study patients were treatment-
naïve. Therefore, one might argue that the likelihood of ﬁrst attempt
treatment responses (measured by changes in Y-BOCS score percent-
ages), is greater in patients with more severe OCS. However, limited
literature investigating treatment response in treatment naïve pa-
tients restrains ﬁrmer speculations.
4.2. Neuropsychological predictors of treatment response
4.2.1. Verbal IQ, verbal memory and learning
The association of higher verbal IQ and better response to CBTmay be
a consequence of the fact that patientswith greater verbal repertoiremay
better understand CBT techniques. Therefore, patients with superior ver-
bal skills are better candidates for cognitive restructuration (Kuelz et al.,
2006). Our ﬁndings suggested that verbal IQ also predicted treatment
response to ﬂuoxetine in a much lesser extent. This supports the concept
that IQ, in general, is a good predictive measure of treatment outcome
(Buitelaar et al., 1995). Likewise, the association between higher perfor-
mance on verbal learning memory tasks (CVLT-II on Trials 1–5 correct)
and better response to both treatments reinforce a general concept that
patients with greater cognitive abilities (a brain with more functional
reserve) are candidates to better respond to treatment (Spreen and
Strauss, 1998).
4.2.2. Executive functions
Fewer perseverations predicting a better response to CBT andworse
ﬂuoxetine response suggest that OCD patients with different mental
ﬂexibility proﬁles may preferentially respond to one type of treatment
versus the other. In addition, our results corroborate previous studies
showing that executive dysfunction is related to a worse prognosis in
patients with OCD who are receiving CBT (Flessner et al., 2010). Fewer
perseverations are a marker of better mental ﬂexibility (Cavedini et al.,
2002; Kuelz et al., 2004), which is certainly advantageous in the setting
of learning alternative behaviors as demanded in CBT. Conversely,
more perseverations have been reported to be associated with a better
response to ﬂuoxetine (Fontenelle et al., 2001). There is evidence
suggesting that altered serotonergic function, a neurotransmission sys-
tem by which SRIs exert its action in the prefrontal cortex (El Mansari
and Blier, 2006), relates to deﬁcits in mental ﬂexibility in OCD patients
(Hollander and Wong, 1996). Therefore, our results suggest that more
impaired mental ﬂexibility should be better acknowledged as a tailoring
variable for determining ﬂuoxetine treatment response.Regarding VST, better inhibitory control was predictive of better
treatment response to both treatments. In previous studies, failure
in this domain has been postulated as an endophenotype in OCD
(Lennertz et al., 2012; Rajender et al., 2011) and has been associated
with treatment response to antidepressants in anxiety disorders
(Bespalov et al., 2010). In the CBT context, having a more efﬁcient in-
hibitory control may help individuals with OCD to inhibit maladap-
tive behaviors in order to generate newer adaptive responses. In
addition, given that antidepressants modulate serotonergic neuro-
transmission in prefrontal regions (El Mansari and Blier, 2006), sub-
jects with a more preserved cognition, evidentiated by a better
performance in inhibitory control, are also prone to respond to SRIs.
5. Limitations
This study must be interpreted in the light of some limitations. First,
the small sample size and the heterogeneous nature of our participants
with respect to their psychiatric comorbiditiesmay have added variability
to our ﬁndings. Thus, our results should be considered exploratory and
our ﬁndings deserve independent replication before generalization.
Second, unexpectedly, somebaselineperformancemeasures, such as sim-
ilarities in the WASI and total recall in the CVLT-II, differed between
groups, which may limit the interpretation of our data. However, it
must be acknowledged that the perseveration scores did not differ
between groups, reinforcing that this characteristic (cognitive rigidity)
indeed shows an opposite effect on treatment response across the two
groups.
6. Conclusion
Our study showed that better cognitive performance (i.e., intelli-
gence, verbal memory/learning and inhibitory control) predicts better
response to treatment regardless of treatment modality in OCD. On
the other hand, given the opposite inﬂuence of mental ﬂexibility in
predicting treatment response to CBT and ﬂuoxetine our results high-
light that different neuropsychological performances may be involved
in treatment response for each intervention. Therefore, depending on
individual neuropsychological proﬁle, treatment response to a given
intervention may differ suggesting that particular treatment can be
assigned according to speciﬁc neuropsychological features (e.g.: OCD
patients with higher verbal IQ and less perseveration tend to respond
better to CBT, whereas subjects with better inhibitory control, but
more perseverationsmay respond better to ﬂuoxetine). Further studies
with larger samples of OCD patients are necessary to investigate the
heuristic value of such measures in a clinical context.
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